alexa Strategic Approaches To Optimize The Power Of Bioequivalence Studies Of Highly Variable Drugs Through Pharmacogenomics
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Francisco E Estevez-Carrizo
Accepted Abstracts: J Bioequiv Availab
DOI: 10.4172/0975-0851.S1.019
Abstract
I n bioequivalence studies of highly variable drugs, intra-individual variability is usually greater than in other studies (CVw>30%). This makes it necessary to significantly increase the number of subjects so as to attain an adequate statistical power. The conventional two-periods, two-sequences, crossover studies rule out between subject variability but variability within subjects remains. Then, to be able to compare the fraction absorbed between reference and test drugs with reasonable accuracy and precision, it is important that the subjects? clearance remains steady through both periods. Subjects with high CVw in drug bioavailability could show differences in drug plasma concentrations, between formulations, due to their inherent between-period changes in metabolism. This might not be fully related to differences in the absorption of formulations under comparison. Regulatory agencies have introduced special study designs in order to address this problem and the latter leads to laborious study conduction and tricky statistics. However, it can be expected that the inclusion of subjects with reduced metabolic enzyme capacity in the study might decrease CVw and hence sample size and cost. The drug metabolizing enzyme genes CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 account of more than 40% of the metabolism of the most frequently prescribed drugs. For example, genetic polymorphism of CYP2D6 influence pharmacokinetic of mitazapine with a 79% increase in AUC for poor vs. extensive metabolizer. On the other hand, for CYP3A5*1/*3* and CYP3A5*3/*3 genotypes, tacrolimus clearance is 16 ml/min/mg and 6 ml/min/mg, respectively. During this speech, the strategic approach to increase bioequivalence study power will be developed.
Biography
Francisco E Estevez-Carrizo got his MD at the State University in Montevideo in 1980. In 1981, he did his Post-doctoral in Clinical Pharmacology at the Karolinska Institute, Stockholm. He was a Fulbright Scholar at Penn State University in 1991. In 1984 he was a resident and board certificate specialist in Clinical Pharmacology. From 1993 he worked as Associate Professor of Pharmacology and Therapeutics at the State University, Montevideo. In 2002, he was appointed as full Professor of Clinical Pharmacology at the University of Montevideo. Currently he is working as a Chief Medical Officer at the Center for Clinical Pharmacology Research in Montevideo, Uruguay. His research interests include Bioequivalence/Pharmacogenomics. He has authored several articles published in peer reviewed journals
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version